SSC Sessions

The annual ISTH Scientific and Standardization Committee (SSC) subcommittee sessions took place from June 22-July 11, prior to the main ISTH 2020 Congress program. 

Sessions are now archived through the ISTH Academy and the Academy App. Watch the archived recordings here

 

Take these two steps to view the SSC Sessions:

  1. Join the ISTH here if you aren't already a member (Academy membership is free).

  2. Then, watch your favorite sessions here.

 

See below for the sessions covered

  • Pediatrics and Neonatal

    • Are Asymptomatic Venous Thromboembolism in Children Clinically Relevant?

    • International Pediatric Thrombosis Network (IPTN): Status Quo and Real-World Use of DOACs in Children: An International Registry 

    • International Pediatric Extracorporeal Membrane Oxygenation (ECMO) Consortium (IPEC): Proposal

    • Pulmonary Embolism Working Group - Project Update​

  • Lupus Anticoagulant/Antiphospholipid Antibodies

    • Altered Platelet Proteome in Lupus Anticoagulant-Positive Patients—Protein Disulfide Isomerase and Netosis as New Players in LA-Related Thrombosis

    • Beyond Antiphospholipid Antibody Detection: Artificial Intelligence for Diagnosing APS

    • Update on the Skylark Project and the Nymphea Project 

    • Multicenter Study on Solid Phase Assays: Detection of Anti-Domain I β2 Glycoprotein I Antibodies by an In-House Assay and a Commercial Chemiluminescent Assay 

    • Multicenter Study on Solid Phase Assays: Role of Immunoglobulin G and Immunoglobulin M Antiphosphatidylserine/Prothrombin Antibodies in Antiphospholipid Syndrome

    • Evaluation of External Quality Control Results: Lupus Anticoagulants Reporting and Qualitative Reporting of Anti-Cardiolipin and Anti-β2-Glycoprotein I

    • Use of Direct Oral Anticoagulants in Antiphospholipid Syndrome Guidance and Registry​

    • Update of the Guidelines for Lupus Anticoagulant Detection and Interpretation – Guidance

  • Models of Thrombosis and Hemostasis​

    • Can Models Influence the Results? Proplatelet Formation: Influence of in Vivo, ex Vivo and in Vitro Models

    • Models of Myelofibrosis: Similitudes and Differences

    • Role of Platelets in Sepsis and Netosis: Differences Between Models 

    • Caveats of Mouse Breeding

    • Three-Dimensional Coculture Models to Analyze the Cross-Talk Between Endothelial Cells, Smooth Muscle Cells, Platelets, and Other Cellular Elements​

  • Vascular Biology​

    • Update on the Comparison Study of Assays to Measure Procoagulant Extracellular Vesicles in Plasma Samples

    • Standardization of Concentration Measurements of Platelet-Derived Extracellular Vesicles for Medical Diagnoses

    • Different Approaches and Considerations in the Detection of Extracellular Mitochondria

    • Detection of Ectopic Coagulation Factor Synthesis in Circulating Blood Cells

    • Do NETs contribute to COVID-19 Pathology?

    • Update on the Standardization of Neutrophil Extracellular Traps Measurements in Patient Samples

    • Methods Used to Quantify and Culture Human Endothelial Colony-Forming Cells: Results of an International Survey

    • Endothelial Progenitors and Vascular Regeneration: Molecular Pathways

    • Identification of Platelet Activation Markers Predictive of Cardiovascular Events: An Update​

  • Perioperative and Critical Care Thrombosis and Hemostasis (COVID-19 Focus: New Concepts in VTE Prophylaxis and Coagulation Management)​

    • Current and Future Research Projects

    • Thromboinflammation and Therapeutic Strategies

    • How Much Anticoagulation is Enough?

    • Venous Thromboembolism Prevention in Critical Care

    • Venous Thromboembolism Prevention in Hospitalized Patients

    • Hemostatic Changes​

  • Von Willebrand Factor

    • Guidelines for the Diagnosis and Management of Von Willebrand Disease

    • COVID-19, Von Willebrand Factor and Pulmonary Thrombosis

    • Vasculopathy in COVID-19

    • Von Willebrand Disease in Elderly Patients

    • Low Von Willebrand Factor in Young Children

    • Neuraxial Anesthesia in Women With Bleeding Disorders             

    • International Microangiopathic Thrombocytopenia ADAMTS13 Standardization (IMATAS) Collaborative Study - Project Update

    • Standardization of Von Willebrand Disease Nomenclature: Type 1C Von Willebrand Disease and Type 2M (Platelet Binding Defect; Collagen Binding Defect) ​

  • Women's Health​ Issues in Thrombosis and Hemostasis

    • Immune Thrombocytopenia and Obstetric Neuraxial Anesthesia at Low Platelet Counts-An International Registry​

    • Guidance on the Management of Women with Type 2B von Willebrand Disease During Pregnancy and Postpartum 

    • Anticoagulation for Patients With Mechanical Heart Valves During Pregnancy: A Survey 

    • Retrospective Obstetric Study in Severe Congenital Protein C Deficiency

    • Registry and International Efforts Around Hemophilia Carriers 

    • Recurrent Failures in Assisted Reproductive Techniques: The FIRST Registry and What Next 

    • Tranexamic Acid: What is the Optimal Dose to Prevent Severe Obstetrical Hemorrhage 

    • COVID-19 Coagulopathies and Pregnancy - including Live Q&A

  • Disseminated Intravascular Coagulation​

    • Coagulation and Neutrophil Extracellular Traps

    • D-Dimer and Fibrinolysis in Sepsis

    • The Coagulopathies of the Viral Hemorrhagic Fevers

    • Endotheliopathy in Septic Conditions

    • The Position of D-Dimer Antigen in Diagnosis of Intravascular Coagulation and the Issue of Common Calibration of D-Dimer Assays

    • Diagnosis and Management of Disseminated Intravascular Coagulation in Pregnancy in Kingdom of Saudi Arabia

    • Optimal Patient Selection for Anticoagulant Therapy in Sepsis Cases Based on the Modified Japanese Association for Acute Medicine Disseminated Intravascular Coagulation Criteria​

  • Joint Session: Plasma Coagulation Inhibitors, Pediatrics, Women's Health

    • Function of Protein C​

    • Laboratory Testing for Protein C

    • Clinical Presentation and Diagnosis of Severe Congenital Protein C Deficiency

    • Management of Severe Congenital Protein C Deficiency During Childhood

    • Prognosis of Severe Congenital Protein C Deficiency and Management of Subsequent Pregnancies

  • Factor XI and the Contact System

    • Is the Contact Activation System a Potential Therapeutic Target in Patients with COVID-19?

    • Genetics of Factor XI Deficiency

    • Plasma Prekallikrein and High Molecular Weight Kininogen Deficiency Registry

    • Therapeutic Strategies to Control Contact Activation

    • COSYNE: Contact System Network

    • How to Handle and Study Polyphosphate​

  • Joint Session:  Lupus Anticoagulant/Antiphospholipid Antibodies and Control of Anticoagulation​​​

    • Use of DOAC in Antiphospholipid Syndrome - Guidance and Registry​

    • Lupus Anticoagulant Testing in Samples From Anticoagulated Patients - Guidance

    • How to Measure Lupus Anticoagulants During DOAC Treatment

    • Which Patients With New Venous Thromboembolism in Whom a DOAC Is Considered Should Be Tested for Anti-Phospholipid Autoantibodies

    • Antiphospholipid Antibodies in COVID-19 Patients

    • Point-Of-Care Testing International Normalized Ratio Monitoring in Antiphospholipid Syndrome Patients - Proposal for Project

    • Management of Arterial Thrombotic Antiphospholipid Syndrome

    • Management of Anticoagulants in Obstetrical Antiphospholipid Syndrome 

    • Report on the HIBISCUS Study

  • Genomics in Thrombosis and Hemostasis

    • A Novel Gene Variant Driving Platelet Thrombin/Protease-Activated Receptor 4  Activation via a Non-Coding Mechanism

    • Genetic Variants Creating Premature ATG, a Neglected Class of Non-Coding 5’UTR Variations Implicated in Human Diseases – Illustration on Thrombotic Cases

    • 50,000 Whole-Genome Sequences and Hemostasis Phenotypes: Expanding Genomic Discovery

    • Hemostasis/Thrombosis Gene Curation to Inform Clinical Gene Testing Panel Development

    • STRIDE: A Collaborative, Prospective Study for Best Practices in Platelet Transcriptomics

    • Gold Variant Database

    • Guidelines Related to Ethics and Consenting

  • Predictive/Diagnostic Variables ​​​

    • Progress on the Common Data Element Project in Venous Thromboembolism by the SSC ​

    • Standards for Diagnosis of Pulmonary Embolism and Deep Vein Thrombosis in Cancer Patients 

    • Risk Factors and Predictors of Venous Thromboembolism in Stroke – a Systematic Review 

    • Assessment of Bleeding Risk During Anticoagulant Treatment for Venous Thromboembolism

    • Identification of Novel Biomarkers for Venous Thromboembolism Recurrence

    • Predictive Accuracy of Clinical Decision Rules and D-Dimer in Suspected Pulmonary Embolism - Individual Participant Data Meta-Analysis 

  • Control of Anticoagulation​

    • SSC Guidance on Combining Anticoagulants and Antiplatelet Agents

    • Low Molecular Weight Heparin Anti-Xa Thresholds for Using a Reversal Agent

    • International Registry on the Diagnosis and Treatment of Inferior Vena Cava Thrombosis

    • Post-Bleed Management of Antithrombotic Therapy Values and Preferences (PANTHER-VP): A Mixed-Methods Study of Healthcare Providers

    • Bleeding and Thrombotic Events After Resumption of Oral Anticoagulants Following Gastrointestinal Bleeding 

    • Anticoagulant Therapy for Splanchnic Vein Thrombosis

    • International Registry on the Use of the Direct Oral Anticoagulants for the Treatment of Unusual Site Venous Thromboembolism

    • Standardization of The Definition of Clinical Outcome For Patients Treated For A Major Oral Anticoagulant Related Bleed​

  • Fibrinolysis​

    • WHO Standardization Projects – Streptokinase, D-Dimer and Plasminogen Activator Inhibitor-1​

    • Update on SSC Project: The Assessment of Fibrinolytic Resistance in Septic Patients Using the ROTEM Velocity Curves of Clot Formation

    • Dynamic Changes in Fibrinolysis During Liver Transplantation:  How Flow Based Measurements of Coagulation Correlate to TEG Output in Quantification of Fibrinolytic Activity

    • Tissue Plasminogen Activator Therapy for COVID-19 Respiratory Failure

    • Simultaneous Quantitation of Thrombin and Plasmin Generation in Patients With Disorders of Fibrinolysis

    • Functional Assays to Evaluate Total Thrombin-Activatable Fibrinolysis Inhibitor Active Enzyme Potential

    • Use of Euglobulin Clot Lysis Assay to Standardize Murine Clot Lysis

  • Platelet Physiology

    • Standardizing Platelet Transcriptomics for Discovery, Diagnostics, and Therapeutics in the Thrombosis and Hemostasis Community (STRIDE) Study: An Update​

    • A Multicentric Comparison of Platelet Aggregation Agonists Against NIBSC Standards: An Update

    • Standardization of Mouse Models Involving Platelet Depletion and Infusion: New Project

    • COVID and Platelets: The Italian Experience

    • Immunothrombosis During Clinical COVID-19 disease

  • Factor XIII and Fibrinogen​

    • Rapid Paper Diagnostics for Measuring Blood Fibrinogen Concentration

    • Uncovering the Molecular Structure of Fibrin Clots

    • Long-Term Controllable Knockdown of Factor XIII Using Sirna and the Impact on Fibrinolysis, Thrombolysis, Bleeding and Rebleeding

    • Mechanisms of Resistance – the Importance of Histone-Fibrinogen Interactions

    • Update on the WHO 3rd International Standard for Thrombin

    • Completion of Value Assignment for Total Factor XIII-B Subunit to the WHO 1st International Standard for Factor XIII Plasma (02/206)​

  • Plasma Coagulation Inhibitors

    • SSC Guideline on Clinical Laboratory Testing for Antithrombin​

    • Antithrombin Deficiency Registry

    • Antithrombin Resistant Prothrombin Yukuhashi

    • SSC Guideline on Clinical Laboratory Testing for Activated Protein C Resistance

    • Classification of Protein S Deficiency: Keeping up With Evolving Knowledge

    • Anti-Tissue Factor Pathway Inhibitor: Clinical Significance of Therapeutic and Auto Antibodies

    • Clinical Significance of Heparin-Like Glycosaminoglycan in Blood and Urine

  • Factor VIII, Factor IX and Rare Coagulation Disorders​

    • The Target Factor Level Post Gene Therapy Should Be a Normal Factor Level

    • Immune Tolerant Induction Is Irrelevant in Thrombosis and Hemostasis Era of Non-Replacement Therapies

    • Management of a Hemophilia Patient with COVID-19 Requiring Prohemostatic Agents

    • What Should Be the Endpoints in Non-Factor Therapies in Hemophilia. Do These Need Standardization?

    • Why the Same Dose of Adeno-Associated Virus Transgene Yields Different Results: Is This a Standardization Issue?

    • Chromogenic Versus One Stage Measurements in Extended Half-Life Products in a Field Study

    • Chromogenic Versus One Stage Assay Measurements in a FIX Padua Field Study​

  • Joint Session:  Dissemintate Intravascular Coagulation, Fibrinolysis, Perioperative and Critical Care Thrombosis and Hemostasis

    • Introduction: Coagulopathy Conundrums in COVID-19​

    • Thrombotic Features of COVID-19

    • Fibrinolytic Shutdown in Sepsis and COVID-19

    • COVID-19 Hypercoagulability and HIT

    • Anticoagulant Therapies for DIC in COVID-19: Roles for Serine Protease Inhibitors

    • Clinical Approach to Hypercoagulability in Critically Ill Patients

  • Biorheology​

    • Modeling Hemodynamics of Venous Thrombosis and Its Consequences With A Vascularized Vein-chip

    • Platelet-Fibrin Formation Under Flow: Obstacles and Opportunities

    • Using Static Mixers For Coagulation In Microfluidic Flow-based Assays 

    • Regulation of Coagulation by Flow: A Primer

    • New SSC Project on In Vitro Approach To Study Turbulence Using Small Sample Volumes 

    • Future SSC Project on Cellular Interactions In Flowing Blood​

  • Platelet Immunology​

    • Update on Implementation of Human Platelet Antigen-1 (HPA-1) Screening in Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT) Risk Management

    • Standardization of Clinical Outcomes in Immune Thrombocytopenic Purpura 

    • Autoantibody-Mediated Desialylation Impairs Thrombopoiesis 

    • Anti-alpha2-Macroglobulin 5B9 as an Internal Quality Control for Functional Assays

    • Rapid HIT Diagnostic Assays: Where Do We Stand? ​

  • Hemostasis and Malignancy​

    • COVID-19 and Malignancy 

    • Management of Coagulopathy of Leukemia: Guidance Proposal

    • Standards for Diagnosing Venous Thromboembolism in Cancer

    • Anticoagulation in Brain Tumors

    • IMPEDE Score Validation in Myeloma Patients

    • Use of DOACS in Cancer Associated Thrombosis​

  • Joint Session: Platelet Immunology and Physiology

    • Collaborative Project Proposal: Guidance Regarding Platelet Function Testing in Patients With Low Platelet Counts ​

    • Megakaryopoiesis and Thrombopoiesis in Immune Thrombocytopenia

    • Platelet FC Gamma Type 2 Receptor A (FCγRiia) Receptor in Immunity and Thrombosis

Tel: +1 919 929 3807

Fax: +1 919 929 3935
meetings@isth.org

International Society on Thrombosis and Haemostasis (ISTH) 
610 Jones Ferry Road, Suite 205 Carrboro, NC 27510 USA
© COPYRIGHT 2019. ALL RIGHTS RESERVED

  • Facebook - Black Circle
  • Twitter - Black Circle
  • LinkedIn - Black Circle
  • Instagram - Black Circle
  • YouTube - Black Circle